Clinical Trial

Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 12, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-02; most recent amendment 2025-09-07.
Status change: Not Yet Recruiting → Recruiting 2023-10-09
Trial Details
NCT Number NCT05939674
Lead Sponsor Pusan National University Yangsan Hospital
Conditions Flumazenil Adverse Reaction, Remimazolam, Hip Joint, Elderly Patients
Enrollment 24 participants
Start Date 2023-09-19
Primary Completion 2026-02 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-12